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Supplementary Information 
Supplemental Experimental Procedures  
Label free proteomics 
Gel electrophoresis and trypsin digest: The supernatants of siScramble- and siTbk1-
treated lysates were extracted and protein concentration was determined using Bradford 
assay, and 20 µg of each sample was loaded onto a 4-12% Bis-Tris poly-acrylamide gel 
(Invitrogen, Carlsbad, CA) for electrophoresis. Gel was stained with BioSafe Coomassie 
according to directions supplied by company (BioRad, Hercules, CA), each gel lane was 
divided into 6 segments down the length of the lane. Each gel segment (6 per sample) 
was excised, cut into 1-2 mm pieces and transferred to 0.5 ml tubes for in-gel digest. 
Proteins were destained with 40% acetonitrile with 50mM Tris (pH 8.1) until clear, 
reduced with 50 mM TCEP in 50 mM Tris (pH 8.1) for 40 minutes at 60°C, followed 
with alkylation using 25 mM iodoacetamide in 50 mM Tris (pH 8.1) for 40 minutes in the 
dark at room temperature. Proteins were digested in-situ with 0.16 µg trypsin (Promega 
Corporation, Madison WI) in 25 mM Tris pH 8.1 and 0.0002% Zwittergent 3-16, 
overnight at 37°C, followed by peptide extraction with 4% trifluoroacetic acid and 
acetonitrile. Extractions were dried and stored at -20°C.  
Mass spectrometry: Dried trypsin digested samples were suspended in 0.2% formic 
acid/0.1% TFA/0.002% zwittergent 3-16. A portion of the sample was analyzed by nano-
flow liquid chromatography electrospray tandem mass spectrometry (nanoLC-ESI-
MS/MS) using a Thermo Scientific Q-Exactive Mass Spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) coupled to a Thermo Ultimate 3000 RSLCnano HPLC 
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system. The digest peptide mixture was loaded onto a 330 nL Halo 2.7 ES-C18 trap 
(Optimize Technologies, Oregon City, OR). Chromatography was performed using A 
solvent (98% water/2% acetonitrile/0.2 % formic acid) and B solvent (80% 
acetonitrile/10% isopropanol/10% water/0.2% formic acid), over a 2% to 45% B gradient 
for 90 minutes at 400 nL/min through a PicoFrit (New Objective, Woburn, MA) 100 µm 
x 33 cm column hand packed with Agilent Poroshell 120 EC C18 packing (Agilent 
Technologies, Santa Clara, CA). Q-Exactive mass spectrometer was set to acquire an ms1 
survey scans from 350-1600 m/z at resolution 70,000 (at 200 m/z) with an AGC target of 
3e6 ions and a maximum ion inject time of 60 msec. Survey scans were followed by 
HCD MS/MS scans on the top 15 ions at resolution 17,500 with an AGC target of 2e5 
ions and a maximum ion inject time of 60 msec. Dynamic exclusion placed selected ions 
on an exclusion list for 40 seconds.  
Data analysis: MaxQuant software (Max Planck Institute of Biochemistry, Martinsried, 
Germany), version 1.6.0.16, was used for database search, time align, and peak extract 
information from generated mass spectrometry files1. Label free parameters within the 
MaxQuant software were used to generate normalized protein intensities reported in a 
protein groups table. Perseus software (Max Planck Institute of Biochemistry, 
Martinsried, Germany), version 1.6.2.1, was used to perform differential expression of 
identified proteins2. Briefly, protein intensities were log2 transformed, missing values 
were replaced from a normal distribution, Student’s t-test was performed requiring valid 
values to be present in all samples of at least one group, and p-values and q-values were 
reported. Protein groups with a p < 0.05 and a fold change of at least 1.5 were considered 
as significantly differentially expressed. 
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RNA-seq and data analysis 
200 ng of total RNA from each sample was used. The RNA-Seq libraries were generated 
using TruSeq Stranded mRNA Library Prep kit (Illumina, CA) at Medical Genome 
Facility according to the manufacturer’s protocol. Constructed libraries were quantified 
by BioAnalizer 2100 system using D1000 kit (Agilent, CA) and Qubit dsDNA BR Assay 
kits (Thermo Fisher Scientific, MA). All libraries were pooled and sequenced 101 bp 
paired-end reads on Illumina HiSeq 2500 Rapid Run. FASTQ files were uploaded into 
Partek Flow software (Partek Inc., MO) and performed primary QC. The STAR (2.6.1d) 
aligner was used to perform alignment of reads to the rn6 build of the Rattus norvegicus 
full reference genome. After alignment, the final BAM files were quantified using Partek 
E/M algorithm3 by Ensembl annotations (rn6 ensemble release96 v2). DESeq2 package4 
was used to normalize data and determine differential expression of RNA-Seq between 
two groups. The false discovery rate (FDR) by Benjamin and Hochberg method was used 
to adjust for comparison. FDR value less than 0.05 and fold change ±1.5 at raw P value 
less than 0.05 were considered as significant change. Hierarchical clustering was 
performed on the significantly changed genes based on the Euclidean distance and the 
average linkage clustering algorithm using Partek Flow software. To further understand 
the biological meaning of the data set, Gene Set Enrichment Analysis (GSEA, Broad 
Institute) was carried out in Molecular Signatures Database v5.2 (MsigDB). 
 
Ki67-postive cell counting 
Human islets  
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To calculate the number of proliferating β-cells in dissociated cultured human islets, the 
total number of Ki67+ and INSULIN+ double positive cells in each well was manually 
counted using a Zeiss LSM 700-405 confocal microscope. The total number of 
INSULIN+ cells in each well was estimated approximately by multiplying the number of 
INSULIN+ cells in a single cluster of islet and the total number of clusters with 
INSULIN+ cells. 
STZ-induced diabetic mice  
To calculate the number of proliferating β-cells, images of >10 islets in two 8 µm-thick 
pancreas sections (separated by 400 µm) per animal were taken using a Zeiss LSM 700-
405 confocal microscope. The number of Ki67+ and Insulin+ double positive cells, and 
the total number of Insulin+ cells in the same islet were counted with ImageJ (20 planes 
of confocal images; N = 3 mice per group).  
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Supplemental Figure Legends 
Supplementary figure 1. Quantification of colocalization of TBK1 with C-Peptide 
and Glucagon. Total 681 (C-Peptide-positive), 587 (TBK1-positive), and 197 
(Glucagon-positive) cells were counted.   
 
Supplementary figure 2. IKKe is specifically expressed in non-b-cells, primarily in 
a-cells, in adult human pancreatic islets. (A-A’) Confocal images of adult human 
pancreatic tissues, stained for IKKe (green), C-Peptide (red), and DAPI (blue). IKKe is 
expressed in non-b-cells in pancreatic islets. (B-B’’’) Confocal images of adult human 
pancreatic islets, stained for IKKe (green), C-Peptide (red), and Glucagon (blue), 
showing IKKe expression in non-b-cells, primarily in a-cells. Magnified images of a 
white square in B are shown in B’-B’’’. N = 3 donors. Scale bars: 50 µm.  
 
Supplementary figure 3. Full western blot scans for Figure 2C. The full scans for 
each blot are shown right.  
 
Supplementary figure 4. Full western blot scans for Figure 3G. The full scans for 
each blot are shown right.  
 
Supplementary figure 5. Proteomic analysis of Tbk1-depleted INS-1 832/13 b-cells 
displays decrease in expression of proteins involved in b-cell maturity. (A) Top focus 
proteins decreased in Tbk1-depleted INS-1 832/13 b-cells. (B-C) Two top protein 
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network interactomes generated from focus and reference proteins identified in siTbk1-
treated relative to control b-cells, converging onto vacuolar H+-ATPase (B; ATP6V1A, 
ATP6V1B2, ATP6V1E1; green asterisks) and mitochondrial complex 1 (C; NDUFB10, 
NDUFC2; green asterisks). Red and green intensities indicate upregulated and 
downregulated protein expression, respectively. Gray indicates protein was detected but 
did not meet focus protein threshold criteria. Solid and dashed line indicate a direct or 
indirect interaction, respectively.  
 
Supplementary figure 6. Full western blot scans for Figure 3H. The full scans for 
each blot are shown right.  
 
Supplementary figure 7. Genetic silencing of TBK1 leads to dysregulated insulin 
secretion. (A) Glucose-stimulated insulin secretion (GSIS) under basal (2.8 mM glucose) 
followed by stimulatory (16.7 mM) conditions in siScramble (control)- and siTbk1-
treated INS-1 832/13 rat β-cells. (B) Fold change in GSIS in INS-1 832/13 rat β-cells 
treated with siTbk1 as compared to control. 3 sample sets per treatment, triplicate per 
each sample set. All values, mean ± SEM. Two-way ANOVA (A) or unpaired two-tailed 
t-test (B). Asterisk indicates statistical significance: *, P < 0.05; **, P < 0.01; n.s., not 
significant. 
 
Supplementary figure 8. TBK1-PDE3B axis regulates proliferation of b-cells via 
cAMP-PKA and mTORC1 signaling cascade. (A-B) Representative Western blot 
showing increased phosphorylation of PKA substrate (A) and mTORC1 target RPS6 (B) 
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in siTbk1-treated INS-1 832/13 b-cells. (C) myc-RAPTOR were transfected into INS-1 
832/13 b-cells for 48 hours, followed by immunoprecipitation from cell lysates with anti–
c-Myc–conjugated beads and incubation with PKA catalytic (cPKA) subunit. Western 
blot analysis was performed with anti-p-PKA substrate (phospho-Ser/Thr residue of 
RRXS/T motif) and anti-Myc antibodies. (D) Representative Western blot analysis of 
whole cell lysates from INS-1 832/13 b-cells expressing empty vector or HA-TBK1, and 
treated with or without 25 µM forskolin for 30 min, showing decreased p-PKA substrate 
levels  in TBK1 overexpressing cells. (E) RT-qPCR analysis of proliferation gene Ki67 in 
INS-1 832/13 b-cells expressing empty vector, HA-TBK1, or myc-PDE3B, and treated 
with or without 10 µM cilostamide or 25 µM forskolin for 30 min. One-way ANOVA. 
Asterisk indicates statistical significance: *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. 
(F) Representative Western blot analysis of whole cell lysates from INS-1 832/13 b-cells 
expressing myc-PDE3B. (G-G’’’’’) Confocal images of adult human pancreatic islets, 
stained for TBK1 (green), PDE3B (blue), and C-Peptide (red). TBK1 and PDE3B are 
specifically expressed in pancreatic b-cells. Magnified images of TBK1, PDE3B, and C-
Peptide expression in b-cells (white squares in G and G’) are shown in G’’-G’’’’’. N = 3 
donors. Scale bar: 50 µm. (H) Schematic of the hypothetical TBK1-PDE3 axis that 
modulates cAMP-PKA-mTORC1 signaling cascade for proliferation of b-cells. The sites 
of inhibition by PIAA and cilostamide are shown in red; activation by forskolin (Fsk) in 
black arrow.  
 
Supplementary figure 9. Full western blot scans for Supplementary Figure 8A. The 
full scans for each blot are shown right.  
 9 
 
Supplementary figure 10. Full western blot scans for Supplementary Figure 8B. The 
full scans for each blot are shown right.  
 
Supplementary figure 11. Full western blot scans for Supplementary Figure 8C. The 
full scans for each blot are shown right.  
 
Supplementary figure 12. Full western blot scans for Supplementary Figure 8D. The 
full scans for each blot are shown right.  
 
Supplementary figure 13. Full western blot scans for Supplementary Figure 8F. The 
full scans for each blot are shown right.  
 
Supplementary figure 14. PIAA derives its mitogenic effects primarily via inhibition 
of TBK1 and augments expression of cell cycle control molecules and b-cell 
differentiation markers in INS-1 832/13 b-cells. (A-B) RT-qPCR analysis of 
proliferation gene Ki67 (A) and Mafa (B) in siScramble (control)-, siTbk1-treated, and 
siTbk1 plus PIAA-treated INS-1 832/13 b-cells. (C-E) RT-qPCR analysis of cell cycle 
regulators Ccnd1 (C) and Ccnd3 (D), and Mafa (E) in DMSO- and PIAA-treated INS-1 
832/13 b-cells. Gene expression was normalized to that of Gapdh and presented as fold 
changes (±SEM) against control expression. 3 sample sets per treatment, triplicate per 
each sample set. One-way ANOVA (A-B) and unpaired two-tailed t-test (C-E). Asterisk 
indicates statistical significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 
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0.0001; n.s., not significant.  
 
Supplementary figure 15. PIAA enhances expression of cell cycle control molecules 
and b-cell differentiation markers in human embryonic stem cell (hESC)-derived b-
cells. (A) RT-qPCR analysis of TBK1 and IKBKE in hESC-derived b-cells. (B-D) RT-
qPCR analysis of cell cycle regulator CCND1 (B) and b-cell genes that confer mature 
features INS (C) and MAFA (D) in DMSO- and PIAA-treated hESC-derived b-cells. 
Gene expression was normalized to that of GAPDH and presented as fold changes 
(±SEM) against control expression. 3 sample sets per treatment, triplicate per each 
sample set. Unpaired two-tailed t-test. Asterisk indicates statistical significance: *, 
P < 0.05; ***, P < 0.001; ****, P < 0.0001.  
 
Supplementary figure 16. PIAA improves glucose control and β-cell mass in the 
STZ-induced diabetic mouse model. (A) RT-qPCR analysis of Tbk1 in STZ-induced 
mice (N =3 mice per group for pancreas; N = 4 mice per group for liver). (B-F) STZ-
induced diabetic mice were treated with vehicle or PIAA for 3 weeks after reaching 
 > 300 mg/dL fed glucose values. (B) PIAA caused reduction of hyperglycemia (non-
fasting glucose measurement) relative to vehicle-treated animals. N = 5 mice per group. 
(C) PIAA-treated animals showed improved glucose tolerance. diabetic: N = 7 mice; 
diabetic plus PIAA: N = 6 mice. (D-E) Confocal images of diabetic pancreata treated 
with vehicle (D) and PIAA (E), respectively, stained for Ki67 (red, white arrows), Insulin 
(green), and Glucagon (blue). (F) The percentage (± SEM) of Ki67 and Insulin-double 
positive cells in diabetic islets with or without PIAA treatment in D and E. A minimum 
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of 829 (diabetic) and 959 (diabetic plus PIAA) insulin-positive cells were counted (10 
islets/treatment). Two-way repeated measures ANOVA followed by Bonferroni's 
multiple comparisons (B and C) and Unpaired two-tailed t-test (F). Asterisk indicates 
statistical significance: ****, P < 0.0001. 
 
Supplementary figure 17. Full western blot scans for Figure 8D. The full scans for 
each blot are shown right.  
 
Supplementary figure 18. PIAA restores the expression of proliferation genes and b-
cell differentiation markers under glucolipotoxic condition. RT-qPCR analysis of 
proliferation gene Ki67 (A) and cell cycle regulator Ccnd1 (B), and β-cell maturation 
genes Mafa (C) and Ins2 (D) in low glucose (5 mM), glucolipotoxic (25 mM glucose plus 
0.2 mM palmitate, 48-hour treatment), and glucolipotoxic plus PIAA-treated INS-1 
832/13 rat β-cells. 3 sample sets per treatment, triplicate per each sample set. All values, 
mean ± SEM. One-way ANOVA. Asterisk indicates statistical significance: *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., not significant. LG, low glucose; 
HGL, high glucose and lipotoxic.  
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Supplementary Table 1. Top Focus Proteins and Associated Canonical Pathways 
Identified in Tbk1-depleted INS-1 832/13 b-cells 
Name Description Canonical pathway Fold 
change 
P value 
RPL11 60S ribosomal 
protein L11 
EIF2, eIF4/p70S6K, 
mTOR signaling 
1.56 4.519E-04 
RPL4 60S ribosomal 
protein L4 
EIF2, eIF4/p70S6K, 
mTOR signaling 
3.89 1.056E-05 
RPL3 60S ribosomal 
protein L3 
EIF2, eIF4/p70S6K, 
mTOR signaling 
5.62 2.356E-03 
RPL39 60S ribosomal 
protein L39 
EIF2, eIF4/p70S6K, 
mTOR signaling 
8.29 1.569E-05 
RPS29 40S ribosomal 
protein S29 
EIF2, eIF4/p70S6K, 
mTOR signaling 
4.79 1.671E-04 
RPS11 40S ribosomal 
protein S11 
EIF2, eIF4/p70S6K, 
mTOR signaling 
2.26 2.557E-05 
RPL7 60S ribosomal 
protein L7 
EIF2, eIF4/p70S6K, 
mTOR signaling 
8.24 2.963E-05 
RPL15 60S ribosomal 
protein L15 
EIF2, eIF4/p70S6K, 
mTOR signaling 
5.38 2.251E-05 
RPS7 40S ribosomal 
protein S7 
EIF2, eIF4/p70S6K, 
mTOR signaling 
2.28 1.191E-03 
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RPS6 40S ribosomal 
protein S6 
EIF2, eIF4/p70S6K, 
mTOR signaling 
4.06 3.292E-04 
RPS15 40S ribosomal 
protein S15 
EIF2, eIF4/p70S6K, 
mTOR signaling 
2.0 1.596E-03 
RPS16 40S ribosomal 
protein S16 
EIF2, eIF4/p70S6K, 
mTOR signaling 
6.06 6.626E-04 
RPL6 60S ribosomal 
protein L6 
EIF2, eIF4/p70S6K, 
mTOR signaling 
6.42 3.031E-6 
RPS5 40S ribosomal 
protein S5 
EIF2, eIF4/p70S6K, 
mTOR signaling 
3.30 1.532E-04 
RPL18 60S ribosomal 
protein L18 
EIF2, eIF4/p70S6K, 
mTOR signaling 
4.60 5.325E-04 
RPS14 40S ribosomal 
protein S14 
EIF2, eIF4/p70S6K, 
mTOR signaling 
1.85 1.198E-03 
RPLP0 60S acidic 
ribosomal protein 
P0 
EIF2, eIF4/p70S6K, 
mTOR signaling 
3.13 1.401E-06 
TOP2A DNA 
topoisomerase 2-
alpha 
Cell cycle 1.51 7.986E-05 
TOP2B DNA 
topoisomerase 2-
beta 
Cell cycle 1.84 9.794E-04 
RFC1 Replication Factor 
C Subunit 1 
NER pathway 2.28 8.427E-05 
MKi67 Marker of 
proliferation Ki-67 
 7.85 3.567E-06 
NDUFB10 NADH:ubiquinone 
oxidoreductase 
subunit B10 
Sirtuin signaling -1.74 3.184E-04 
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ATP6V1A ATPase H+ 
transporting V1 
subunit A 
Phagosome maturation -1.64 1.855E-05 
ATP6V1B2 ATPase H+ 
transporting V1 
subunit B2 
Phagosome maturation -1.53 1.654E-03 
ATP6V1E1 ATPase H+ 
transporting V1 
subunit E1 
Phagosome maturation -1.68 1.009E-05 
HMGCS1 3-hydroxy-3-
methylglutaryl-
coA synthase 1 
Mevalonate pathway -3.36 3.192E-05 
SLC25A10 Solute Carrier 
Family 25 Member 
10 
 -1.50 1.673E-04 
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Supplementary Table 2. PCR primers used for RT-qPCR  
Name Sequence 
CCND1 forward TCTACACCGACAACTCCATCCG 
CCND1 reverse TCTGGCATTTTGGAGAGGAAGTG 
CCND3 forward AGATCAAGCCGCACATGCGGAA 
CCND3 reverse ACGCAAGACAGGTAGCGATCCA 
Ki67 forward TCCTTTGGTGGGCACCTAAGACCTG 
Ki67 reverse TGATGGTTGAGGTCGTTCCTTGATG 
INS forward TCACACCTGGTGGAAGCTCTCTA 
INS reverse ACAATGCCACGCTTCTGCAGGGAC 
MAFA forward GAGCGGCTACCAGCATCAC 
MAFA reverse CTCTGGAGTTGGCACTTCTCG 
GAPDH forward GTCTCCTCTGACTTCAACAGCG 
GAPDH reverse ACCACCCTGTTGCTGTAGCCAA 
Rat Ki67 forward ATTTCAGTTCCGCCAATCC  
Rat Ki67 reverse GGCTTCCGTCTTCATACCTAAA  
Rat Mafa forward AGGAGGTCATCCGACTGAAACA 
Rat Mafa reverse GCGTAGCCGCGGTTCTT 
Rat Ins2 forward GGTTCTCACTTGGTGGAAGCTC 
Rat Ins2 reverse GTGCCAAGGTCTGAAGGTCAC 
Rat Glut2 forward TAGTCAGATTGCTGGCCTCAGCTT 
Rat Glut2 reverse TTGCCCTGACTTCCTCTTCCAACT 
 
 


















